[HTML][HTML] Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

…, C Avgoustou, S Chalvatzis, T Marantos… - The Lancet …, 2021 - thelancet.com
Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …

An open label trial of anakinra to prevent respiratory failure in COVID-19

…, A Stamou, T Gkavogianni, K Katrini, T Marantos… - Elife, 2021 - elifesciences.org
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR ≥6 ng/ml …

[PDF][PDF] Multi-cohort analysis of host immune response identifies conserved protective and detrimental modules associated with severity across viruses

…, Y Su, CL Dai, SA Kornilov, M Karagiannis, T Marantos… - Immunity, 2021 - cell.com
Viral infections induce a conserved host response distinct from bacterial infections. We
hypothesized that the conserved response is associated with disease severity and is distinct …

Clinical characteristics and outcomes of measles outbreak in adults: A multicenter retrospective observational study of 93 hospitalized adults in Greece

…, M Pirounaki, H Sambatakou, T Marantos… - Journal of Clinical …, 2020 - Elsevier
Objectives Measles outbreaks are increasingly reported among countries that were close-to-eliminate
measles infection. There are few reports of clinical characteristics of measles in …

Anakinra to prevent respiratory failure in COVID-19

…, A Stamou, T Gkavogianni, K Katrini, T Marantos… - medRxiv, 2020 - medrxiv.org
Introduction The management of pneumonia caused by SARS-CoV-2 should rely on early
recognition of the risk for progression to severe respiratory failure (SRF) and its prevention. …

Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis

T Marantos, E Kyriazopoulou, V Lekakis… - Journal of the …, 2023 - Elsevier
Background Seroconversion rate of vaccines varies and requires further elucidation in
patients with multiple sclerosis (MS) under treatment with disease-modifying therapies (DMTs). …

Linezolid: a promising agent for the treatment of multiple and extensively drug-resistant tuberculosis

DD Fermeli, TD Marantos, ALD Liarakos… - Folia Medica, 2020 - foliamedica.bg
Tuberculosis is a severe, infectious disease caused by Mycobacterium tuberculosis. The
aim of this review was to present the efficacy of linezolid as an agent against multidrug and …

An open label trial of anakinra to prevent respiratory failure in COVID-19

…, S Aliki, G Theologia, K Konstantina, M Theodoros… - eLife, 2021 - search.proquest.com
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR≥ 6 ng/ml …

[PDF][PDF] Multi-cohort analysis of host immune response identifies conserved protective and detrimental modules associated with severity across viruses

…, Y Su, CL Dai, SA Kornilov, M Karagiannis, T Marantos… - Immunity, 2021 - academia.edu
Viral infections induce a conserved host response distinct from bacterial infections. We
hypothesized that the conserved response is associated with disease severity and is distinct …

[HTML][HTML] A cost of illness analysis of hepatocellular carcinoma for the Greek healthcare setting

…, C Psarrakis, N Tziolos, T Marantos… - … and Hepatology From …, 2020 - ncbi.nlm.nih.gov
Aim: To estimate the cost per patient for hepatocellular carcinoma in Greece, a setting that is
currently facing financial constraints. Background: Hepatocellular carcinoma patient …